Cigna Faces Off Against FTC Over CVS Caremark and Pharmacy Benefit Managers
Cigna Takes Legal Action Against FTC
The owner of Cigna, one of the leading pharmacy benefit managers, has initiated legal proceedings to thwart the Federal Trade Commission's (FTC) investigation. This action follows a critical report alleging that pharmacies, including CVS Caremark, engage in practices that inflate drug prices affecting consumers.
Implications for Pharmacy Benefit Managers
The conflict shines a light on the increasing scrutiny faced by pharmacy benefit managers (PBMs) like Express Scripts and OptumRx. Public awareness surrounding the role of these drug middlemen is rising as their practices are scrutinized for potential antitrust violations.
- Cigna aims to safeguard its interests against regulatory challenges.
- CVS Caremark finds itself in the crosshairs of federal investigation.
- Public and governmental focus is sharpening on PBMs and their operations.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.